Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: cirrhosis is the growing burden of hepatitis C virus-related disease DOI
Yen Thi-Hai Pham, Daniel Q. Huang, Zhongjie Zhang

и другие.

European Journal of Cancer Prevention, Год журнала: 2024, Номер unknown

Опубликована: Март 22, 2024

Background Chronic infection with hepatitis C virus (HCV) has a long-term impact on hepatic consequences. A comprehensive evaluation of the global burden HCV-related health outcomes can help to develop HCV prevention and treatment program. Methods We used 2019 Global Burden Disease (GBD) Study comprehensively investigate temporal trends in incidence, mortality disability-adjusted life-years (DALYs) diseases, including liver cancer cirrhosis other diseases across 264 countries territories from 2010 2019. Results Globally, there were 152 225 incident cases, 141 811 deaths approximately 2.9 million DALYs because cancer, 551 668 395 022 about 12.2 Worldwide, during 2010–2019 period, incidence declined, however, was 62% increase incidence. In 2019, Eastern Mediterranean region highest rates both cirrhosis. Africa fastest-growing trend period [annual percentage change (APC) = 2.09, 95% confidence interval (CI): 1.93–2.25], followed by Western Pacific (APC 1.17, CI: 1.09–1.22). Americas only observing increased 0.70 0.12, respectively). identified three patterns that reported rates. Conclusion Urgent measures are required for diagnosis, research at global, regional country levels, particularly Africa, Mediterranean.

Язык: Английский

Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection DOI Open Access
Debika Bhattacharya,

Andrew Aronsohn,

Jennifer C. Price

и другие.

Clinical Infectious Diseases, Год журнала: 2023, Номер unknown

Опубликована: Май 25, 2023

The Infectious Diseases Society of America and the American Association for Study Liver have collaboratively developed evidence-based guidance regarding diagnosis, management, treatment hepatitis C virus (HCV) infection since 2013. A panel clinicians investigators with extensive infectious diseases or hepatology expertise specific to HCV periodically review evidence from field update existing recommendations introduce new as warrants. This focuses on changes previous 2020 published update, including ongoing emphasis recommended universal screening; management incomplete adherence; expanded eligibility simplified chronic in adults minimal monitoring; updated retreatment children young 3 years old; transplantation setting; screening, treatment, unique key populations.

Язык: Английский

Процитировано

146
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology DOI
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal

и другие.

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2023, Номер 20(12), С. 797 - 809

Опубликована: Авг. 3, 2023

Язык: Английский

Процитировано

95
A National Hepatitis C Elimination Program in the United States DOI Open Access

Rachael Fleurence,

Francis S. Collins

JAMA, Год журнала: 2023, Номер 329(15), С. 1251 - 1251

Опубликована: Март 9, 2023

This Viewpoint introduces a proposed 5-year program from the Biden-Harris administration that would use direct-acting antivirals to eliminate hepatitis C in United States.

Язык: Английский

Процитировано

75
The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease DOI Creative Commons
Zobair M. Younossi, Maria Stepanova, Reem Q. Al Shabeeb

и другие.

Hepatology Communications, Год журнала: 2023, Номер 8(1)

Опубликована: Дек. 21, 2023

The high prevalence of obesity in the United States drives burden NASH, recently renamed as metabolic dysfunction-associated steatohepatitis (MASH). We assessed most recent trends liver transplantation States.

Язык: Английский

Процитировано

57
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019 DOI Open Access
Farhad Islami, Emily C. Marlow, Blake Thomson

и другие.

CA A Cancer Journal for Clinicians, Год журнала: 2024, Номер 74(5), С. 405 - 432

Опубликована: Июль 11, 2024

In 2018, the authors reported estimates of number and proportion cancers attributable to potentially modifiable risk factors in 2014 United States. These data are useful for advocating informing cancer prevention control. Herein, based on up-to-date relative occurrence data, estimated invasive cases (excluding nonmelanoma skin cancers) deaths, overall 30 types among adults who were aged years older 2019 States, that factors. included cigarette smoking; second-hand smoke; excess body weight; alcohol consumption; consumption red processed meat; low fruits vegetables, dietary fiber, calcium; physical inactivity; ultraviolet radiation; seven carcinogenic infections. Numbers deaths obtained from sources with complete national coverage, factor prevalence nationally representative surveys, associated risks published large-scale pooled or meta-analyses. 2019, an 40.0% (713,340 1,781,649) all incident 44.0% (262,120 595,737) States evaluated Cigarette smoking was leading contributing (19.3% 28.5%, respectively), followed by weight (7.6% 7.3%, (5.4% 4.1%, respectively). For 19 types, more than one half considered this study. Lung had highest (201,660) (122,740) factors, female breast (83,840 cases), melanoma (82,710), colorectal (78,440) (25,800 deaths), liver (14,720), esophageal (13,600) deaths. Large numbers underscoring potential substantially reduce burden through broad equitable implementation preventive initiatives.

Язык: Английский

Процитировано

54
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions DOI
Lung‐Yi Mak, Ken Liu, Sakkarin Chirapongsathorn

и другие.

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2024, Номер 21(12), С. 834 - 851

Опубликована: Авг. 15, 2024

Язык: Английский

Процитировано

37
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma DOI
Daniel Q. Huang, Joseph Hoang, Rubayet Kamal

и другие.

Journal of Clinical Oncology, Год журнала: 2024, Номер 42(7), С. 790 - 799

Опубликована: Янв. 4, 2024

There are limited data on antiviral treatment

Язык: Английский

Процитировано

20
Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection DOI Open Access
Yu‐Ping Chang,

Ji‐Yuh Lee,

Chi‐Yi Chen

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Фев. 21, 2025

ABSTRACT Background Data regarding the risk of incident type 2 diabetes (T2D) and prediabetes among patients with hepatitis C virus (HCV) achieving direct‐acting antivirals (DAAs)‐induced sustained virologic response (SVR 12 ) remains limited. Methods A total 1079 patients, including 589 normoglycemia 490 prediabetes, who underwent biannual fasting glucose glycosylated haemoglobin (HbA1c) assessment for a median post‐SVR follow‐up 5.5 years, were enrolled. We reported crude (cIRs) age‐standardised incidence rates (ASIRs) T2D prediabetes. Factors associated assessed using Cox proportional hazards models. Results The cIRs 1.18 8.99 per 100 person‐years (PYFU), respectively. Additionally, ASIRs 1.09 (95% CI: 0.76–1.53) 8.47 7.23–9.90) PYFU. Prediabetes (adjusted hazard ratio [aHR]: 4.71; 95% confidence interval (CI): 2.55–8.70, p < 0.001), body mass index (BMI) kg/m increase (aHR: 1.17; 1.09–1.26, 0.001) liver stiffness measurement (LSM) kPa 1.05; 1.02–1.09, = higher T2D. Age year 1.02; 1.01–1.03, was Conclusion remain substantial after HCV eradication. Lifestyle modification, drug therapy regular monitoring glycemic status are crucial at developing following clearance.

Язык: Английский

Процитировано

4
Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040 DOI Creative Commons

Sikai Qiu,

Jiangying Cai, Zhanpeng Yang

и другие.

JAMA Network Open, Год журнала: 2024, Номер 7(11), С. e2445525 - e2445525

Опубликована: Ноя. 18, 2024

Importance The burden of liver cancer varies worldwide. An upward trend in both hepatocellular carcinoma (HCC) incidence and mortality the past 2 decades has been observed. Objective To assess observed HCC-related age-standardized rates (ASMRs) US for 2006 to 2022 provide ASMR projections through 2040. Design, Setting, Participants This cross-sectional study used data from National Vital Statistics System, which is accessible Centers Disease Control Prevention Wide-Ranging Online Data Epidemiologic Research website. on deaths attributed HCC (from January 1, 2006, December 31, 2022) were obtained adults 25 years or older stratified by disease etiology, age, sex, race ethnicity. Etiologies included alcohol-associated (ALD), hepatitis B virus (HBV), C (HCV), metabolic dysfunction–associated steatotic (MASLD). Main Outcomes Measures main outcomes (1) ASMRs per 100 000 persons using Joinpoint regression (National Cancer Institute) trends during (2) projected 2023 2040 Prophet AutoARIMA modeling. Results 188 280 2022. Most occurred among males (77.4%). annual percentage change was 4.1% (95% CI, 2.2% 7.7%) 2009 decreased 1.8% 0.7% 2.0%) 2022, with an overall 5.03 a 6.39 2040, consistent sexes. By HCV- HBV-related but increased ALD- MASLD-related mortality. In MASLD surpassed HBV as third-leading cause death overtake HCV 2032 second-leading cause; ALD be leading 2026. higher individuals aged 65 compared those 64 (18.37 vs 1.79 persons). American Indian Alaska Native population had largest increase (14.71 persons) Asian (3.03 Conclusions Relevance this study, rapidly 2022; ALD-related 2026, 2032. These findings may serve reference public health decision-making timely identification groups at high risk death.

Язык: Английский

Процитировано

5
Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients DOI
Vy H. Nguyen, Daniel Q. Huang, Michael H. Le

и другие.

Liver International, Год журнала: 2023, Номер 43(6), С. 1195 - 1203

Опубликована: Фев. 24, 2023

Global data on the treatment rate with direct-acting antivirals (DAAs) for chronic hepatitis C (CHC) are sparse. We aimed to evaluate CHC and barriers in DAA era.We searched PubMed, EMBASE Cochrane from inception 5 August 2021, relevant articles. Patients treated DAAs without interferon (IFN) therapy were categorized as IFN-free DAAs. receiving IFN or unclear status DAA/IFN.We identified analysed 146 studies (1 760 352 patients). DAA/IFN was 16.0% (95% CI: 9.9-23.3, 49 studies, 886 535 52.3% 46.2-58.4, 123 1 276 754 patients): 45.4% North America, 64.2% South America study), 90.4% Africa (most Egypt), 54.4% Europe, 60.7% Australia 60.5% Asia, (p < .0001); 49% B co-infection 32.3% hepatocellular carcinoma (HCC). Treatment not a priority 22.8% of patients Europe 16.7% Australia, compared only 4.8% 2.1% Asia .0001). Poor adherence clinical follow-up cause no 74.7% 37.0% 7.9% 14.3% .0001).Though marked improvement IFN/DAA, remains suboptimal (52.3% overall, HCC Non-adherence lack disease awareness barriers.

Язык: Английский

Процитировано

11